I believe FSYS was driven down by the news that Iran and Iraq are increasing their oil output and will not adhere to OPEC limits. Either the Saudi's or others will need to limit their output or supply is going to outstrip demand and the price of oil will come down. FSYS needs the nat gas to be significantly cheaper than oil.
4 more Meningitis (B Strain) cases reported at Univ of Cal Santa Barbara. Again a call for Bexsero to available. CDC will have a hard time standing in the way of importing the one vaccine for this strain. A few more outbreaks and the FDA will need to revisit the cost benefit decision on this one.
Princeton Meningitis Outbreak Prompts Vaccine Import to U.S.
By Drew Armstrong & Michelle Fay Cortez - Nov 16, 2013 11:00 PM CT
A meningitis outbreak at Princeton University of a strain not covered by vaccines available in the U.S. has prompted federal health officials to approve import of the drug in an effort to stop the illness.
Trustees at the Princeton, New Jersey-based Ivy League school where at least seven students since March have developed infections with the meningococcus B strain of the bacteria, will consider this weekend whether to use the vaccine, made by Novartis AG (NOVN), said Martin Mbugua, a spokesman for the school.
Enlarge image Princeton University
Pedestrians walk past a statue of former Princeton University president John Witherspoon near the East Pyne building on the school's campus in Princeton, New Jersey. Photographer: Emile Wamsteker/Bloomberg
The outbreak is the first of the meningitis B strain in a specific group, in which health officials have had the option to vaccinate, according to Barbara Reynolds, a spokeswoman for the U.S. Centers for Disease Control and Prevention in Atlanta. The CDC had requested and received permission last week from the Food and Drug Administration to import the vaccine, a necessary protocol since the treatment hasn’t been approved in the U.S.
I followed the Baker Bros and loaded up in the mid 20's. However, there have been several ups and downs since I bought. The downdrafts have been severe enough to make me kick myself for not harvesting some gains by taking something off the table. I'm a strong believer that the prostate test will be a game changer. The Cleveland clinic testing and support bodes well. However, the value will have to be confirmed in several peer reviewed medical journals before there will be really widespread acceptance. Till then I think the sales ramp will be steady in the low double digit range. Eventually insurers will become big backers since the test will save millions of unnecessary procedures. This and geographic expansion will fuel many years of growth I might want to consider a pair trade where I might eventually short the makers/operators of proton treatment for prostate cancer. Competition can always change the landscape but for now GHDX looks to be well situated. I've decided to maintain a strong core holding and write covered calls on about 25% of my holdings when the share price reaches lofty periods.
Unfortunately the past has shown that NVS is too large and diversified to be rocketed by the roll out of any single product. On the plus side, the downside is pretty limited when a product gets yanked from the market or when an approval does not come through (think zelnorm and prexige).